Drug Type Colony-stimulating factors |
Synonyms- |
Target |
Mechanism CSF-2R stimulants(Granulocyte-macrophage colony-stimulating factor receptor stimulants) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
Drug Highest PhasePhase 2 |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Nasopharyngeal Carcinoma | Phase 2 | CN | 15 Sep 2023 | |
Stomatitis | Phase 2 | CN | 15 Sep 2023 |
Phase 2 | Melanoma Adjuvant | 62 | nckuhxwbtt(vciyzubhtt) = at a median follow-up of 79 months, this translated into a significantly longer recurrence-free survival (RFS) in the CpG-treated group (p=0.010) jrloagdxrm (qirmovtdil ) | Positive | 04 Nov 2015 | ||
CpG-B (PF-3512676/CpG7909, 8 mg) |